Market capitalization | $292.61m |
Enterprise Value | $-86.64m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 15.67 |
EV/Sales (TTM) EV/Sales | -0.48 |
P/S ratio (TTM) P/S ratio | 1.61 |
P/B ratio (TTM) P/B ratio | 0.54 |
Revenue growth (TTM) Revenue growth | -23.63% |
Revenue (TTM) Revenue | $182.02m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:
3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 182 182 |
24%
24%
|
|
Gross Profit | 164 164 |
24%
24%
|
|
EBITDA | -27 -27 |
316%
316%
|
EBIT (Operating Income) EBIT | -32 -32 |
436%
436%
|
Net Profit | -11 -11 |
173%
173%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Head office | United States |
CEO | Mihael Polymeropoulos |
Employees | 203 |
Founded | 2002 |
Website | www.vandapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.